Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exubera’s Post-Marketing Safety Program Is Industry Model – Pfizer’s Ryder

Executive Summary

Pfizer's proposed post-marketing studies for the inhaled insulin therapy Exubera exemplify the type of risk management programs FDA should encourage industry to conduct, Pfizer Clinical R&D Senior VP Steven Ryder told an Institute of Medicine committee on Jan. 19
Advertisement

Related Content

Exubera Education, Complicated Manufacturing Impacting Launch Timeline
Pfizer Exubera Has Mid-Year Launch Trigger, Heavy Dose Of Instructions
Phase IV Studies Need Greater Input From FDA, Industry Tells IoM Panel
Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18
Pfizer Exubera Post-Market Training Needs Greater Emphasis – Cmte.
Pfizer/Sanofi’s Exubera May Need More Data In Asthma, COPD Patients
Pfizer/Sanofi’s Exubera May Need More Data In Asthma, COPD Patients
Advertisement
UsernamePublicRestriction

Register

PS046780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel